{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:54:41Z","timestamp":1782575681542,"version":"3.54.5"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CSL Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Complement and pathogenic antibodies act independently and together to mediate the pathology of many autoimmune diseases. To address these drivers of disease, we generated a monoclonal antibody (mAb), CSL305, that binds and inhibits both complement and the neonatal Fc (fragment crystallizable) receptor FcRn. The fragment antigen binding (Fab) portion of CSL305 was engineered to bind both human C2 (huC2) zymogen and the active fragment huC2b to inhibit the classical and lectin complement pathways in vitro, and C3b deposition on primary lung endothelial cells using a 3-dimensional microvascular model system. Engineering of a triple amino acid mutation (\u201cYPY\u201d motif) into the Fc region of CSL305 increased its affinity to FcRn at both acidic and neutral pH, allowing it to also act as a potent FcRn antagonist. Intracellular trafficking experiments demonstrated that CSL305, but not the wild-type (WT) mAb lacking the YPY motif, was able to block immunoglobulin G (IgG) recycling in vitro. The generation of a high resolution 2.6\u212b crystal structure of CSL305 Fab region bound to huC2b showed that the epitope lies directly over the huC2b catalytic triad, providing evidence of its complement mechanism of action as a neutralising mAb. Early pharmacokinetic (PK)\/pharmacodynamic (PD) studies using CSL305 in cynomolgus monkeys demonstrated both complement inhibition and FcRn antagonism in vivo, with reductions in complement classical pathway activity and endogenous IgG observed following single intravenous (IV) administration. CSL305 thus represents a dual-functional mAb as a potential therapeutic candidate.<\/jats:p>","DOI":"10.3390\/ijms27052383","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:11:36Z","timestamp":1772629896000},"page":"2383","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CSL305: A Dual Functional Therapeutic Antibody Targeting Complement C2 and FcRn"],"prefix":"10.3390","volume":"27","author":[{"given":"Sandra","family":"Wymann","sequence":"first","affiliation":[{"name":"CSL Biologics Research Centre, Swiss Institute for Translational and Entrepreneurial Medicine, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo A. V.","family":"Morales","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Hong","family":"Toh","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Remlinger","sequence":"additional","affiliation":[{"name":"CSL Biologics Research Centre, Swiss Institute for Translational and Entrepreneurial Medicine, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Guse","sequence":"additional","affiliation":[{"name":"CSL Biologics Research Centre, Swiss Institute for Translational and Entrepreneurial Medicine, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Ghai","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Pestel","sequence":"additional","affiliation":[{"name":"CSL Behring Innovation GmbH, 35033 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Sansome","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Guang","family":"Chen","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Rayzman","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-3346","authenticated-orcid":false,"given":"Jenny","family":"Chia","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Quek","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-8245","authenticated-orcid":false,"given":"Michael A.","family":"Gorman","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partho","family":"Halder","sequence":"additional","affiliation":[{"name":"CSL Behring Innovation GmbH, 35033 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Powers","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Ruthsatz","sequence":"additional","affiliation":[{"name":"CSL Behring GmbH, Austria Campus 6, 1020 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-1138","authenticated-orcid":false,"given":"Michael W.","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Australia"},{"name":"Structural Biology Laboratory and ACRF Rational Drug Discovery Centre, St Vincent\u2019s Institute of Medical Research, Fitzroy, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Rowe","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Vyas","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Verhagen","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1953-2018","authenticated-orcid":false,"given":"Matthew P.","family":"Hardy","sequence":"additional","affiliation":[{"name":"CSL Ltd., Bio21 Institute, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: A comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/BOR.0000000000000633","article-title":"Complement, infection, and autoimmunity","volume":"31","author":"Conigliaro","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103303","DOI":"10.1016\/j.jaut.2024.103303","article-title":"Antigen-specific T cells and autoimmunity","volume":"148","author":"Rojas","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhou, Y., and Jiang, S. (2023). Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker. Pathogens, 12.","DOI":"10.3390\/pathogens12060817"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: The changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e179742","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: The future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1080\/00207454.2022.2153046","article-title":"Neuromyelitis optica spectrum disorder: Pathophysiological approach","volume":"134","author":"Ortiz","year":"2024","journal-title":"Int. J. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e3644","DOI":"10.1002\/brb3.3644","article-title":"Neuromyelitis optica spectrum disorder: Exploring the diverse clinical manifestations and the need for further exploration","volume":"14","author":"Noori","year":"2024","journal-title":"Brain Behav."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.kint.2024.10.018","article-title":"Lupus nephritis: Redefining the treatment goals","volume":"107","author":"Sethi","year":"2025","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Roveta, A., Parodi, E.L., Brezzi, B., Tunesi, F., Zanetti, V., Merlotti, G., Francese, A., Maconi, A.G., and Quaglia, M. (2024). Lupus Nephritis from Pathogenesis to New Therapies: An Update. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168981"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Loriamini, M., Cserti-Gazdewich, C., and Branch, D.R. (2024). Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202403.0755.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","article-title":"Autoimmune haemolytic anaemias","volume":"10","author":"Michel","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/B978-0-323-98818-6.00023-6","article-title":"Autoimmune inflammatory myopathies","volume":"195","author":"Dalakas","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"ref_15","first-page":"84","article-title":"Dermatomyositis: A comprehensive review of clinical manifestations, serological features, and therapeutic approaches","volume":"158","author":"Didona","year":"2023","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/B978-0-323-98818-6.00004-2","article-title":"Autoimmune polyneuropathies","volume":"195","author":"Naum","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/ITT.S388151","article-title":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks","volume":"13","author":"Rajabally","year":"2024","journal-title":"Immunotargets Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-Mediated Rejection of Solid-Organ Allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MOT.0000000000001095","article-title":"Role of complement in humoral immunity","volume":"28","author":"Podesta","year":"2023","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MOT.0000000000001131","article-title":"Advances in desensitization for human leukocyte antigen incompatible kidney transplantation","volume":"29","author":"Vo","year":"2024","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1042\/bst0181143","article-title":"Biological functions of the complement system","volume":"18","author":"Lachmann","year":"1990","journal-title":"Biochem. Soc. Trans."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., and Roumenina, L.T. (2015). Complement System Part I\u2014Molecular Mechanisms of Activation and Regulation. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00262"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Merle, N.S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., and Roumenina, L.T. (2015). Complement System Part II: Role in Immunity. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00257"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41581-023-00704-1","article-title":"Complosome\u2014The intracellular complement system","volume":"19","author":"West","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1074\/jbc.M109.081828","article-title":"Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding","volume":"285","author":"Andersen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: Approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/JBM.S362220","article-title":"Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH","volume":"14","author":"Weitz","year":"2023","journal-title":"J. Blood Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29245\/2578-3009\/2022\/4.1240","article-title":"Soluble Complement Receptor 1 Therapeutics","volume":"6","author":"Hardy","year":"2022","journal-title":"J. Immunol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100200","DOI":"10.1074\/jbc.RA120.016127","article-title":"A novel soluble complement receptor 1 fragment with enhanced therapeutic potential","volume":"296","author":"Wymann","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/13543784.2024.2394186","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: Results from a Phase 1, randomized, open-label trial","volume":"33","author":"Li","year":"2024","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Silence","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: First Approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bohlson, S.S., Garred, P., Kemper, C., and Tenner, A.J. (2019). Complement Nomenclature\u2014Deconvoluted. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01308"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: An immunoglobulin variable domain sequence analysis tool","volume":"41","author":"Ye","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/19420862.2017.1359455","article-title":"Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn","volume":"9","author":"Yang","year":"2017","journal-title":"MAbs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jmb.2006.12.039","article-title":"The crystal structure of C2a, the catalytic fragment of classical pathway C3 and C5 convertase of human complement","volume":"367","author":"Krishnan","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement. Second of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1073\/pnas.82.2.488","article-title":"Rapid and efficient site-specific mutagenesis without phenotypic selection","volume":"82","author":"Kunkel","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-1-0716-3381-6_23","article-title":"High-Throughput IgG Reformatting and Expression Using Hybrid Secretion Signals and InTag Positive Selection Technology","volume":"2702","author":"Sansome","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1042\/BCJ20220054","article-title":"Sialylation-dependent pharmacokinetics and differential complement pathway inhibition are hallmarks of CR1 activity in vivo","volume":"479","author":"Wymann","year":"2022","journal-title":"Biochem. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"107451","DOI":"10.1016\/j.jbc.2024.107451","article-title":"Mechanistic insights into complement pathway inhibition by CR1 domain duplication","volume":"300","author":"Wymann","year":"2024","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1038\/s41598-018-24273-7","article-title":"3D artificial round section micro-vessels to investigate endothelial cells under physiological flow conditions","volume":"8","author":"Sfriso","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1242\/bio.20122204","article-title":"SNX5 is essential for efficient macropinocytosis and antigen processing in primary macrophages","volume":"1","author":"Lim","year":"2012","journal-title":"Biol. Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1107\/S0909049502015170","article-title":"Blu-Ice and the Distributed Control System: Software for data acquisition and instrument control at macromolecular crystallography beamlines","volume":"9","author":"McPhillips","year":"2002","journal-title":"J. Synchrotron Radiat."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1107\/S0907444909047374","article-title":"Integration, scaling, space-group assignment and post-refinement","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1107\/S0907444905036693","article-title":"Scaling and assessment of data quality","volume":"62","author":"Evans","year":"2006","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1107\/S0907444905001617","article-title":"Likelihood-enhanced fast translation functions","volume":"61","author":"McCoy","year":"2005","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: Model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1107\/S0907444902016657","article-title":"PHENIX: Building new software for automated crystallographic structure determination","volume":"58","author":"Adams","year":"2002","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1107\/S2059798318005119","article-title":"Structural analysis of glycoproteins: Building N-linked glycans with Coot","volume":"74","author":"Emsley","year":"2018","journal-title":"Acta Crystallogr. D Struct. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:14:41Z","timestamp":1772630081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052383"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052383","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}